2020
Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV
Eyawo O, Deng Y, Dziura J, Justice AC, McGinnis K, Tate JP, Rodriguez‐Barradas M, Hansen NB, Maisto SA, Marconi VC, O’Connor P, Bryant K, Fiellin DA, Edelman EJ. Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV. Alcohol Clinical And Experimental Research 2020, 44: 2053-2063. PMID: 33460225, PMCID: PMC8856627, DOI: 10.1111/acer.14435.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useSignificant alcohol useHeavy drinking daysAlcohol use disorderTimeline FollowbackAlcohol useSelf-reported alcohol useNumber of drinksClinical trialsRisk drinkingUse disordersDrinking daysBiomarker-based evidenceSample of PWHDrinks/dayMean numberSelf-reported alcohol consumptionMagnitude of associationBlood spot samplesLiver diseasePEth levelsTLFB interviewAlcohol consumptionLogistic regressionPatients
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2011
Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya
Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, Songole R, Omolo OE, Kamanda AM, Ayuku DO, Ojwang C, Owino‐Ong'or W, Harrington M, Bryant KJ, Carroll KM, Justice AC, Hogan JW, Maisto SA. Treatment outcomes of a stage 1 cognitive–behavioral trial to reduce alcohol use among human immunodeficiency virus‐infected out‐patients in western Kenya. Addiction 2011, 106: 2156-2166. PMID: 21631622, PMCID: PMC3208780, DOI: 10.1111/j.1360-0443.2011.03518.x.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAlcohol useDrinking daysLarge human immunodeficiency virusCognitive behavioral therapy interventionAlcohol intervention studyAlcohol use disorderGroup Cognitive Behavioral Therapy InterventionEffect sizeTreatment effect sizeCognitive behavioral therapyDual epidemicsRandomized participantsPatient clinicImmunodeficiency virusPreliminary efficacyHuman immunodeficiencyClinical trialsTreatment outcomesAlcohol abstinenceAssessment-only controlBinge drinkingUse disordersTherapy interventionFeasible intervention
2005
A Temporal and Dose‐Response Association Between Alcohol Consumption and Medication Adherence Among Veterans in Care
Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JF, Justice AC. A Temporal and Dose‐Response Association Between Alcohol Consumption and Medication Adherence Among Veterans in Care. Alcohol Clinical And Experimental Research 2005, 29: 1190-1197. PMID: 16046874, DOI: 10.1097/01.alc.0000171937.87731.28.Peer-Reviewed Original ResearchConceptsAlcohol consumptionDose-response relationshipTime-Line FollowNonbinge drinkersHIV individualsMedication adherencePoor adherenceBinge drinkersDrinking daysVeterans Aging Cohort StudyDose-response associationAging Cohort StudySelf-reported alcohol consumptionTelephone interview surveyCohort studyMedication dosesPrescribed medicationsObservational studyInterview SurveyDrinkersAdherenceSame dayDosesAbstainersCare